In Vitro and In Vivo evaluation of novel anticancer agents in triple negative Breast Cancer Models

Johnson, KiTani Parker; Yearby, Letitia; Stoute, Diana; Burow, Matthew E.; Rhodes, Lyndsay V.; Gray, Marian; Carriere, Patrick P.; Tilghman, Syreeta L.; McLachlan, John A.; Ochieng, Josiah

doi:10.1353/hpu.2013.0047

Cited by 11 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proliferation assays were performed as previously described [ 26 ]. Specifically, the AC-1 and LTLT-Ca cells were plated in 96-well plates at a density of 1 × 10 3 cells per well for each cell line and allowed to recover for 24 h. Pharmacological treatments were added containing either the vehicle or 10 μM glyceollin I in four wells each.…”

Section: Methodsmentioning

confidence: 99%

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1

Carriere

Llopis

Naiki

et al. 2015

IJERPH

Self Cite

View full text Add to dashboard Cite

Although aromatase inhibitors are standard endocrine therapy for postmenopausal women with early-stage metastatic estrogen-dependent breast cancer, they are limited by the development of drug resistance. A better understanding of this process is critical towards designing novel strategies for disease management. Previously, we demonstrated a global proteomic signature of letrozole-resistance associated with hormone-independence, enhanced cell motility and implications of epithelial mesenchymal transition (EMT). Letrozole-resistant breast cancer cells (LTLT-Ca) were treated with a novel phytoalexin, glyceollin I, and exhibited morphological characteristics synonymous with an epithelial phenotype and decreased proliferation. Letrozole-resistance increased Zinc Finger E-Box Binding Homeobox 1 (ZEB1) expression (4.51-fold), while glyceollin I treatment caused a −3.39-fold reduction. Immunofluorescence analyses resulted of glyceollin I-induced increase and decrease in E-cadherin and ZEB1, respectively. In vivo studies performed in ovariectomized, female nude mice indicated that glyceollin treated tumors stained weakly for ZEB1 and N-cadherin and strongly for E-cadherin. Compared to letrozole-sensitive cells, LTLT-Ca cells displayed enhanced motility, however in the presence of glyceollin I, exhibited a 68% and 83% decrease in invasion and migration, respectively. These effects of glyceollin I were mediated in part by inhibition of ZEB1, thus indicating therapeutic potential of glyceollin I in targeting EMT in letrozole resistant breast cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1

Carriere

Llopis

Naiki

et al. 2015

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…TNBC corresponds to 15-20% of breast cancers (5) with the worst prognosis, no approved targeted therapies, and usual chemotherapy as the main systemic therapy (6). TNBC lacks three receptors: estrogen, progesterone, and Her2/neu, which are targets for pharmacological treatment (7). TNBC tumors are linked to an increased size of the tumor and higher incidence of axillary node positivity (8), presenting a more aggressive disease, and elevated chances of having axillary lymph node metastases (9).…”

mentioning

confidence: 99%

The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells

et al. 2019

View full text Add to dashboard Cite

Background/Aim: Triple-negative breast cancer (TNBC) is the most aggressive subtype, predominant in African American women. In this study, the antioxidant/anticancer activity of muscadine grape extracts and the role of their phenolic and flavonoid contents in exerting these properties were investigated in TNBC cells. Materials and Methods: Berry extracts from muscadine genotypes were investigated for total phenolic content (TPC), total flavonoid content (TFC), antioxidant capacity, and anticancer effects using breast cancer cell lines, representing Caucasians and African Americans. Results: The antioxidant activity was associated with high TPC content. Extracts showed cytotoxicity up to 78.6% in Caucasians and 90.7% in African American cells, with an association with high antioxidant capacity. There was a strong correlation between TPC and anticancer/antioxidant activities. Conclusion: The anticancer and antioxidant effects of muscadine grapes are attributed to the TPC of extracts, which showed a stronger positive correlation with growth inhibition of African American breast cancer cells compared to Caucasians.

show abstract

“…Additionally, the data indicated that blueberries as daily nutraceutical (6 ounces/day) may be beneficial in cancer prevention (46). The anticancer activity of Mangifera zeylanica (MZ), and of flavonoids from the bark of this plant, endemic to Sri Lanka, was demonstrated in TNBC (47); other prior reports have also indicated the antiproliferative effects of flavonoids in TNBC (48). The bark extracts contain polyphenols and flavonoids, and were used to perform dose-dependent studies to explore the cytotoxic effects of MZ.…”

Section: Phytochemicals Used In Tnbc Treatmentmentioning

confidence: 95%

“…Therefore, the evidence suggests that phytochemicals exhibit chemotherapeutic and chemopreventive properties in TNBC (48). Further investigations into the use of phytochemicals as chemotherapeutic agents are warranted.…”

Section: Phytochemicals Used In Tnbc Treatmentmentioning

confidence: 99%

Phytochemicals: Current strategies for treating breast cancer (Review)

et al. 2018

View full text Add to dashboard Cite

Females with early-stage metastatic, estrogen-dependent breast cancer are generally treated with surgery, radiation and chemotherapy, or with more targeted approaches such as aromatase inhibitors (anastrozole or letrozole) or anti-estrogens (tamoxifen). Despite widespread successful usage of these agents for the treatment of breast cancer, resistance, tumor relapse and metastasis remain the principal causes of mortality for patients with breast cancer. While numerous groups have made major contributions toward an improved understanding of resistance mechanisms, the currently insufficient grasp of the most critical pathways involved in resistance is evident in the inability to adequately treat and drastically improve patient outcomes in females with hormone-refractory breast cancer, including triple negative breast cancer. Therefore, further investigation of novel therapeutic approaches is paramount to reveal previously unconsidered agents that could be utilized to treat metastatic disease. Numerous naturally occurring phytochemicals have recently gained interest as potential therapeutic breast cancer agents appear to directly affect estrogen-dependent and estrogen-independent breast cancer cell proliferation, potentially via affecting breast cancer stem cell populations. While numerous natural compounds have exhibited promise, they are limited by their bioavailability. Therefore, to effectively treat future hormone-refractory breast tumors, it is critical to adequately refine and formulate these agents for effective therapeutic use and delivery. Herein, the literature on the current state of phytochemicals is reviewed, including their limitations and potential as targeted therapies for breast cancer.

show abstract

In Vitro and In Vivo evaluation of novel anticancer agents in triple negative Breast Cancer Models

Cited by 11 publications

References 22 publications

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1

The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells

Phytochemicals: Current strategies for treating breast cancer (Review)

Contact Info

Product

Resources

About